Skeletal health: Primate model of postmenopausal osteoporosis

American Journal of Primatology

Volumn 71, Issue 9, 2009, Pages 752-765

  Smith, S Y ^a   Jolette, J ^a   Turner, C H ^b  

^a IUPUI ^*

^b Indiana University Purdue University Indianapolis   (United States)

Author keywords

Bone; Bone density; Osteoporosis; Ovariectomy

Indexed keywords

BIOMECHANICS; DISEASE TREATMENT; DRUG DEVELOPMENT; ESTROGENIC COMPOUND; GUIDELINE; HORMONE; IMMUNITY; OSTEOLOGY; PRIMATE; REPRODUCTIVE CYCLE; WOMENS HEALTH;

ANIMAL; BIOASSAY; BONE DENSITY; DISEASE MODEL; DRUG EFFECT; DRUG TOXICITY; FEMALE; HUMAN; MACACA; METABOLIC BONE DISEASE; METABOLISM; OVARIECTOMY; POSTMENOPAUSE OSTEOPOROSIS; REVIEW;

ANIMALS; BONE DENSITY; BONE DISEASES, METABOLIC; DISEASE MODELS, ANIMAL; DRUG TOXICITY; ENDPOINT DETERMINATION; FEMALE; HUMANS; MACACA FASCICULARIS; OSTEOPOROSIS, POSTMENOPAUSAL; OVARIECTOMY;

ANIMALIA; PRIMATES;

EID: 69349085848     PISSN: 02752565     EISSN: 10982345     Source Type: Journal    
DOI: 10.1002/ajp.20715     Document Type: Review

References (60)

1. Ahlborg HG, Johnell O, Turner CH, Rannevik G, Karlsson MK. 2003. Bone loss and bone size after menopause. N Engl J Med 349:327-334.
2. Balena R, Toolan BC, Shea M, Markatos A, Myers ER, Lee SC, Opas EE, Seedor JG, Klein H, Frankenfield D, et al. 1993. The effects of 2-year treatment with the aminobispho-sphonate alendronate on bone metabolism, bone histomorphometry, and bone strength in ovariectomized nonhuman primates. J Clin Invest 92:2577-2586.
3. Binkley N, Kimmel D, Bruner J, Haffa A, Davidowitz B, Meng C, Schaffer V, Green J. 1998. Zoledronate prevents the development of absolute osteopenia following ovariectomy in adult rhesus monkeys. J Bone Miner Res 13:
4. Boivin G, Meunier PJ. 2002. Changes in bone remodeling rate influence the degree of mineralization of bone. Connect Tissue Res 43:535-537.
5. Bone HG, Bolognese MA, Yuen CK, Kendler DL, Wang H, Liu Y, San Martin J. 2008. Effects of denosumab on bone mineral density and bone turnover in postmenopausal women. J Clin Endocrinol Metab 93:2149-2157.
6. Brommage R. 2001. Perspectives on using nonhuman primates to understand the etiology and treatment of postmenopausal osteoporosis. J Musculoskelet Neuronal Interact 1: 307-325.
7. Brommage R, Hotchkiss CE, Lees CJ, Stancill MW, Hock JM, Jerome CP. 1999. Daily treatment with human recombinant parathyroid hormone-(1-34), LY333334, for 1 year increases bone mass in ovariectomized monkeys. J Clin Endocrinol Metab 84:3757-3763.
8. Burr DB. 1992. Estimated intracortical bone turnover in the femur of growing macaques: implications for their use as models in skeletal pathology. Anat Rec 232:180-189.
9. Burr DB, Hirano T, Turner CH, Hotchkiss C, Brommage R, Hock JM. 2001. Intermittently administered human parathyroid hormone(1-34) treatment increases intracortical bone turnover and porosity without reducing bone strength in the humerus of ovariectomized cynomolgus monkeys. J Bone Miner Res 16:157-165.
10. CDC. 1993. Diagnosis, prophylaxis, and treatment of osteoporosis. Am J Med 94:646-650.
11. Champ JE, Binkley N, Havighurst T, Colman RJ, Kemnitz JW, Roecker EB. 1996. The effect of advancing age on bone mineral content of female rhesus monkeys. Bone 19:485-492.
12. CHMP. 2006. Guideline on the evaluation of medicinal products in the treatment of primary osteoporosis. London: European Medicines Agency.
13. Cline JM, Botts S, Lees CJ, Brommage R. 2008. Effects of lasofoxifene on the uterus, vagina, and breast in ovariectomized cynomolgus monkeys (Macaca fascicularis). Am J Obstet Gynecol 199:158. el-8.
14. Compston J, editor. 1993. Osteoporosis. Cambridge: Cambridge University Press. p 29-62.
15. Dickerson SS, Hotchkiss CE. 2008. Relationships between densitometric and morphological parameters as measured by peripheral computed tomography and the compressive behavior of lumbar vertebral bodies from macaques (Macaca fascicularis). Spine 33:366-372.
16. FDA. 1994. Guidelines for preclinical and clincal evaluation of agents used in the prevention or treatment of postmenopausal osteoporosis. In: Products DoMaED, editor. Rockville, MD: Food and Drug Administration.
17. Fontana A, Delmas PD. 2003. Selective estrogen receptors modulators in the prevention and treatment of postmenopausal osteoporosis. Endocrinol Metab Clin North Am 32:219-232.
18. Fox J, Miller MA, Newman MK, Recker RR, Turner CH, Smith SY. 2007a. Effects of daily treatment with parathyroid hormone 1-84 for 16 months on density, architecture and biomechanical properties of cortical bone in adult ovariectomized rhesus monkeys. Bone 41:321-330.
19. Fox J, Miller MA, Newman MK, Turner CH, Recker RR, Smith SY. 2007b. Treatment of skeletally mature ovariectomized rhesus monkeys with PTH(1-84) for 16 months increases bone formation and density and improves trabecular architecture and biomechanical properties at the lumbar spine. J Bone Miner Res 22:260-273.
20. Fox J, Miller MA, Recker RR, Turner CH, Smith SY. 2007c. Effects of treatment of ovariectomized adult rhesus monkeys with parathyroid hormone 1-84 for 16 months on trabecular and cortical bone structure and biomechanical properties of the proximal femur. Calcif Tissue Int 81:53-63.
21. Fox J, Newman MK, Turner CH, Guldberg RE, Varela A, Smith SY. 2008. Effects of treatment with parathyroid hormone 1-84 on quantity and biomechanical properties of thoracic vertebral trabecular bone in ovariectomized rhesus monkeys. Calcif Tissue Int 82:212-220.
22. Hartke J. 1998. Non-primate models of osteoporosis. Lab Anim Sci 48:623-629.
23. Havill LM. 2004. Osteon remodeling dynamics in Macaca mulatta: normal variation with regard to age, sex, and skeletal maturity. Calcif Tissue Int 74:95-102.
24. Heringa M. 2003. Review on raloxifene: profile of a selective estrogen receptor modulator. Int J Clin Pharmacol Ther 41:331-345.
25. Hotchkiss C. 1999. Use of peripheral quantitative computed tomography for densitometry of the femoral neck and spine in cynomolgus monkeys (Macaca fascicularis). Bone 24:101-107.
26. Hotchkiss CE, Stavisky R, Nowak J, Brommage R, Lees CJ, Kaplan J. 2001. Levormeloxifene prevents increased bone turnover and vertebral bone loss following ovariectomy in cynomolgus monkeys. Bone 29:7-15.
27. Itoh F, Kojima M, Furihata-Komatsu H, Aoyagi S, Kusama H, Komatsu H, Nakamura T. 2002. Reductions in bone mass, structure, and strength in axial and appendicular skeletons associated with increased turnover after ovariectomy in mature cynomolgus monkeys and preventive effects of clodronate. J Bone Miner Res 17:534-543.
28. Jayo MJ, Jerome CP, Lees CJ, Rankin SE, Weaver DS. 1994. Bone mass in female cynomolgus macaques: a crosssectional and longitudinal study by age. Calcif Tissue Int 54:231-236.
29. Jerome C. 2004. Hormonal therapies and osteoporosis. ILAR J 45:170-178.
30. Jerome CP. 1998. Primate models of osteoporosis. Lab Anim Sci 48:618-622.
31. Jerome CP, Peterson PE. 2001. Nonhuman primate models in skeletal research. Bone 29:1-6.
32. Jerome CP, Turner CH, Lees CJ. 1997. Decreased bone mass and strength in ovariectomized cynomolgus monkeys (Macaca fascicularis). Calcif Tissue Int 60:265-270.
33. Jerome CP, Johnson CS, Vafai HT, Kaplan KC, Bailey J, Capwell B, Fraser F, Hansen L, Ramsay H, Shadoan M, et al. 1999. Effect of treatment for 6 months with human parathyroid hormone (1-34) peptide in ovariectomized cynomolgus monkeys (Macaca fascicularis). Bone 25: 301-309.
34. JMHW. 1999. Guideline Concerning the Clinical Evaluation Method for Anti-Osteoporosis Agents, Pharmaceutical Examination No. 742. In: management BoH, editor: issued by the Prefecural Bureau Chief, Bureau of Health Management, Section of Examination and Control, Bureau of Drug Safety, Japanese Ministry of Health and Welfare.
35. Johnell O. 1997. The socioeconomic burden of fractures: today and in the 21st century. Am J Med 103:S20-S25.
36. Lees C, Shen V, Brommage R. 2007. Effects of lasofoxifene on bone in surgically postmenopausal cynomolgus monkeys. Menopause 14:97-105.
37. Lees CJ, Ramsay H. 1999. Histomorphometry and bone biomarkers in cynomolgus females: a study in young, mature, and old monkeys. Bone 24:25-28.
38. Lees CJ, Register TC, Turner CH, Wang T, Stancill M, Jerome CP. 2002. Effects of raloxifene on bone density, biomarkers, and histomorphometric and biomechanical measures in ovariectomized cynomolgus monkeys. Menopause 9:320-328.
39. Lewiecki EM, Miller PD, McClung MR, Cohen SB, Bolognese MA, Liu Y, Wang A, Siddhanti S, Fitzpatrick LA. 2007. Two-year treatment with denosumab (AMG 162) in a randomized phase 2 study of postmenopausal women with low BMD. J Bone Miner Res 22:1832-1841.
40. Mashiba T, Hirano T, Turner CH, Forwood MR, Johnston CC, Burr DB. 2000. Suppressed bone turnover by bisphosphonates increases microdamage accumulation and reduces some biomechanical properties in dog rib. J Bone Miner Res 15:613-620.
41. Mashiba T, Turner CH, Hirano T, Forwood MR, Jacob DS, Johnston CC, Burr DB. 2001. Effects of high-dose etidronate treatment on microdamage accumulation and biomechanical properties in beagle bone before occurrence of spontaneous fractures. Bone 29:271-278.
42. Miller L, Weaver D, McAlister J, Koritnik D. 1986. Effects of ovariectomy on vertebral trabecular bone in the cynomolgus monkey (Macaca fascicularis). Calcif Tissue Int 38:62-65.
43. Miller MA, Bare SP, Recker RR, Smith SY, Fox J. 2008. Intratrabecular tunneling increases trabecular number throughout the skeleton of ovariectomized rhesus monkeys treated with parathyroid hormone 1-84. Bone 42:1175-1183.
44. Mori H, Tanaka M, Kayasuga R, Masuda T, Ochi Y, Yamada H, Kishikawa K, Ito M, Nakamura T. 2008. Minodronic acid (ONO-5920/YM529) prevents decrease in bone mineral density and bone strength, and improves bone microarch-itecture in ovariectomized cynomolgus monkeys. Bone 43:840-848.
45. Ominsky MS, Kostenuik PJ, Cranmer P, Smith SY, Atkinson JE 2007. The RANKL inhibitor OPG-Fc increases cortical and trabecular bone mass in young gonad-intact cynomolgus monkeys. Osteoporos Int 18:1073-1082.
46. Ominsky MS, Li X, Asuncion FJ, Barrero M, Warmington KS, Dwyer D, Stolina M, Geng Z, Grisanti M, Tan H-L, et al. 2008. RANKL inhibition with osteoprotegerin increases bone strength by improving cortical and trabecular bone architecture in ovariectomized rats. J Bone Miner Res 23:672-682.
47. Parfitt AM, Drezner MK, Glorieux FH, Kanis JA, Malluche H, Meunier PJ, Ott SM, Recker RR. 1987. Bone histomorphometry: standardization of nomenclature, symbols, and units. Report of the ASBMR Histomorphometry Nomenclature Committee. J Bone Miner Res 2:595-610.
48. Prestwood KM, Gunness M, Muchmore DB, Lu Y, Wong M, Raisz LG. 2000. A comparison of the effects of raloxifene and estrogen on bone in postmenopausal women. J Clin Endocrinol Metab 85:2197-2202.
49. Recker RR, Bare SP, Smith SY, Varela A, Miller MA, Morris SA, Fox J. 2009. Cancellous and cortical bone architecture and turnover at the iliac crest of postmenopausal osteoporotic women treated with parathyroid hormone 1â''84. Bone 44:113-119.
50. Reinhardt V, Hurwitz S. 1993. Evaluation of social enrichment for aged rehesus macaques. Anim Technol 44:53-57.
51. Reinwald S, Burr D. 2008. Review of nonprimate, large animal models for osteoporosis research. J Bone Miner Res 23:1353-1368.
52. Russo CR, Lauretani F, Bandinelli S, Bartali B, Di Iorio A, Volpato S, Guralnik JM, Harris T, Ferrucci L. 2003. Aging bone in men and women: beyond changes in bone mineral density. Osteoporos Int 14:531-538.
53. Sato M, Westmore M, Clendenon J, Smith S, Hannum B, Zeng GQ, Brommage R, CH T. 2000. Three-dimensional modeling of the effects of parathyroid hormone on bone distribution in lumbar vertebrae of ovariectomized cynomolgus macaques. Osteoporos Int 11:871-880.
54. Smith BB, Cosenza ME, Mancini A, Dunstan C, Gregson R, Martin SW, Smith SY, Davis H. 2003a. A toxicity profile of osteoprotegerin in the cynomolgus monkey. Int J Toxicol 22:403-412.
55. Smith SY, Recker RR, Hannan M, Müller R, Bauss F. 2003b. Intermittent intravenous administration of the bisphosphonate ibandronate prevents bone loss and maintains bone strength and quality in ovariectomized cynomolgus monkeys. Bone 32:45-55.
56. Suda T, Takahashi N, Udagawa N, Jimi E, Gillespie MT, Martin TJ. 1999. Modulation of osteoclast differentiation and function by the new members of the tumor necrosis factor receptor and ligand families. Endocr Rev 20:345-357.
57. Turner AS. 2001. Animal models of osteoporosis-necessity and limitations. Eur Cell Mater 1:66-81.
58. Turner CH. 2002. Biomechanics of bone: determinants of skeletal fragility and bone quality. Osteoporos Int 13:97-104.
59. Turner CH, Burr DB. 1993. Basic biomechanical measurements of bone: a tutorial. Bone 14:595-608.
60. WHO. 2004. The World Health Report 2004: changing history.